ロード中...
Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia
Ibrutinib is a covalently binding inhibitor of the B-cell receptor signaling-mediator Bruton’s tyrosine kinase (BTK) with great efficacy in chronic lymphocytic leukemia (CLL). Common side effects like atrial fibrillation (AF), bleeding and infections might be caused by ibrutinib’s inhibition of othe...
保存先:
| 出版年: | Hemasphere |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8078281/ https://ncbi.nlm.nih.gov/pubmed/33912812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000564 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|